Pub Date : 2023-09-01Epub Date: 2023-04-26DOI: 10.4168/aair.2023.15.5.673
Ji-Yong Moon, Hyun Lee, Min-Hye Kim, Woo-Jung Song, Sang Min Lee, Sae-Hoon Kim, Sang-Heon Kim, Byung-Jae Lee, Ho Joo Yoon, Sang Hoon Kim
Although postinfectious etiology is the most common cause of subacute cough, there are insufficient data on the epidemiology of associated bacterial infections. We aimed to identify the etiology of bacterial detection in subjects with subacute cough. A multicenter prospective observational study of 142 patients with postinfectious subacute cough was performed between August 2016 and December 2017 in Korea. We obtained 2 nasal swabs from each patient and used a multiplex bacterial polymerase chain reaction (PCR) kit that simultaneously detects Bordetella pertussis, Chlamydophila pneumoniae, Haemophilus influenzae, Legionella pneumophilia, Mycoplasma pneumoniae, and Streptococcus pneumoniae. About 29% (n = 41) of patients with subacute cough were positive for bacterial PCR in nasal swabs. The most common bacteria detected by bacterial PCR was H. influenzae (n = 19, 13.4%), followed by S. pneumoniae (n = 18, 12.7%), B. pertussis (n = 7, 4.9%), M. pneumoniae (n = 3, 2.1%), L. pneumophilia (n = 2, 1.4%), and C. pneumoniae (n = 1, 0.7%). Nine patients had dual positivity for the PCR. In conclusion, bacterial PCR was positive in the nasal swabs of about 29% of subjects with subacute cough, including 5% of positive PCR results for B. pertussis.
{"title":"Bacterial Etiology in Subacute Cough.","authors":"Ji-Yong Moon, Hyun Lee, Min-Hye Kim, Woo-Jung Song, Sang Min Lee, Sae-Hoon Kim, Sang-Heon Kim, Byung-Jae Lee, Ho Joo Yoon, Sang Hoon Kim","doi":"10.4168/aair.2023.15.5.673","DOIUrl":"https://doi.org/10.4168/aair.2023.15.5.673","url":null,"abstract":"<p><p>Although postinfectious etiology is the most common cause of subacute cough, there are insufficient data on the epidemiology of associated bacterial infections. We aimed to identify the etiology of bacterial detection in subjects with subacute cough. A multicenter prospective observational study of 142 patients with postinfectious subacute cough was performed between August 2016 and December 2017 in Korea. We obtained 2 nasal swabs from each patient and used a multiplex bacterial polymerase chain reaction (PCR) kit that simultaneously detects <i>Bordetella pertussis</i>, <i>Chlamydophila pneumoniae</i>, <i>Haemophilus influenzae</i>, <i>Legionella pneumophilia</i>, <i>Mycoplasma pneumoniae</i>, and <i>Streptococcus pneumoniae</i>. About 29% (n = 41) of patients with subacute cough were positive for bacterial PCR in nasal swabs. The most common bacteria detected by bacterial PCR was <i>H. influenzae</i> (n = 19, 13.4%), followed by <i>S. pneumoniae</i> (n = 18, 12.7%), <i>B. pertussis</i> (n = 7, 4.9%), <i>M. pneumoniae</i> (n = 3, 2.1%), <i>L. pneumophilia</i> (n = 2, 1.4%), and <i>C. pneumoniae</i> (n = 1, 0.7%). Nine patients had dual positivity for the PCR. In conclusion, bacterial PCR was positive in the nasal swabs of about 29% of subjects with subacute cough, including 5% of positive PCR results for <i>B. pertussis.</i></p>","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"15 5","pages":"673-681"},"PeriodicalIF":4.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/02/6c/aair-15-673.PMC10570775.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41188242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.4168/aair.2023.15.5.545
Carina Venter
Allergic diseases are increasing both in morbidity and mortality. Genetic, environmental, and dietary factors may all be involved in this increase. Nutrition during pregnancy, breastfeeding, and early life may play a particularly important role in preventing allergic diseases. Based on current systematic reviews, the intake of specific nutrients has failed to prevent allergic disease. Prevention strategies have shifted their focus to the overall diet which can be described using diet diversity. Infant and maternal diet diversity in pregnancy has been associated with reduced allergy outcomes in childhood. Overall, diet also seems to have a marked effect on the microbiome compared to single foods. Factors that may negate the allergy-preventative effect of overall diet diversity include the addition of emulsifiers, advanced glycation end-product content, and overuse of commercial baby foods. There is a need to perform randomized controlled trials using overall dietary intake to support international food allergy guidelines. These studies should ideally be conducted by multi-professional teams.
{"title":"Immunonutrition: Diet Diversity, Gut Microbiome and Prevention of Allergic Diseases.","authors":"Carina Venter","doi":"10.4168/aair.2023.15.5.545","DOIUrl":"10.4168/aair.2023.15.5.545","url":null,"abstract":"<p><p>Allergic diseases are increasing both in morbidity and mortality. Genetic, environmental, and dietary factors may all be involved in this increase. Nutrition during pregnancy, breastfeeding, and early life may play a particularly important role in preventing allergic diseases. Based on current systematic reviews, the intake of specific nutrients has failed to prevent allergic disease. Prevention strategies have shifted their focus to the overall diet which can be described using diet diversity. Infant and maternal diet diversity in pregnancy has been associated with reduced allergy outcomes in childhood. Overall, diet also seems to have a marked effect on the microbiome compared to single foods. Factors that may negate the allergy-preventative effect of overall diet diversity include the addition of emulsifiers, advanced glycation end-product content, and overuse of commercial baby foods. There is a need to perform randomized controlled trials using overall dietary intake to support international food allergy guidelines. These studies should ideally be conducted by multi-professional teams.</p>","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"15 5","pages":"545-561"},"PeriodicalIF":4.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c5/83/aair-15-545.PMC10570780.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41188247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: Allergic rhinitis (AR) is a T helper type 2 (Th2)-mediated inflammatory disease. The E3 ligase tripartite motif-containing 24 (TRIM24) regulates the recruitment of acetyltransferase CREB-binding protein (CBP) to signal transducer and activator of transcription 6 (STAT6). CBP mediates the acetylation of STAT6 and decreases its activity. To date, the precise role of TRIM24 in AR has not been fully interpreted. Herein, our study aimed to explore the functions of TRIM24 in AR.
Methods: The expression of TRIM24 in peripheral blood mononuclear cells (PBMCs) and CD4+ T cells from patients with AR was measured. TRIM24-conditional knockout mice with TRIM24 deficiency in CD4+ T cells were generated. Wide-type (WT) AR mice and TRIM24-conditional knockout AR mice were established. Then, AR symptoms and interleukin (IL)-4 levels were compared. Further, the proliferation, activation and polarization of CD4+ T cells from WT mice and TRIM24 knockout mice after stimulation were determined. The effects of TRIM24 deficiency on STAT6 activities were also evaluated.
Results: Downregulated TRIM24 expression was detected in PBMCs and CD4+ T cells from patients with AR. TRIM24 conditional knockout mice had more sever AR symptoms with elevated IL-4 production. TRIM24-knockout CD4+ T cells had similar proliferation and activation when compared to WT CD4+ T cells, while they had enhanced Th2 polarization. TRIM24-knockout CD4+ T cells had decreased acetylation of STAT6 and enhanced STAT6 activities after IL-4 stimulation. The regulation of STAT6 activities by TRIM24 depended on TRIM24 N terminal RIGN domain and Lys383 acetylation site of STAT6.
Conclusions: TRIM24 suppresses Th2-mediated AR by regulating the acetylation of STAT6.
{"title":"TRIM24-Mediated Acetylation of STAT6 Suppresses Th2-Induced Allergic Rhinitis.","authors":"Liyan Yue, Qiaojing Jia, Jinhui Dong, Jianxing Wang, Xiumin Ren, Ou Xu","doi":"10.4168/aair.2023.15.5.603","DOIUrl":"10.4168/aair.2023.15.5.603","url":null,"abstract":"<p><strong>Purpose: </strong>Allergic rhinitis (AR) is a T helper type 2 (Th2)-mediated inflammatory disease. The E3 ligase tripartite motif-containing 24 (TRIM24) regulates the recruitment of acetyltransferase CREB-binding protein (CBP) to signal transducer and activator of transcription 6 (STAT6). CBP mediates the acetylation of STAT6 and decreases its activity. To date, the precise role of TRIM24 in AR has not been fully interpreted. Herein, our study aimed to explore the functions of TRIM24 in AR.</p><p><strong>Methods: </strong>The expression of TRIM24 in peripheral blood mononuclear cells (PBMCs) and CD4<sup>+</sup> T cells from patients with AR was measured. TRIM24-conditional knockout mice with TRIM24 deficiency in CD4<sup>+</sup> T cells were generated. Wide-type (WT) AR mice and TRIM24-conditional knockout AR mice were established. Then, AR symptoms and interleukin (IL)-4 levels were compared. Further, the proliferation, activation and polarization of CD4<sup>+</sup> T cells from WT mice and TRIM24 knockout mice after stimulation were determined. The effects of TRIM24 deficiency on STAT6 activities were also evaluated.</p><p><strong>Results: </strong>Downregulated TRIM24 expression was detected in PBMCs and CD4<sup>+</sup> T cells from patients with AR. TRIM24 conditional knockout mice had more sever AR symptoms with elevated IL-4 production. TRIM24-knockout CD4<sup>+</sup> T cells had similar proliferation and activation when compared to WT CD4<sup>+</sup> T cells, while they had enhanced Th2 polarization. TRIM24-knockout CD4<sup>+</sup> T cells had decreased acetylation of STAT6 and enhanced STAT6 activities after IL-4 stimulation. The regulation of STAT6 activities by TRIM24 depended on TRIM24 N terminal RIGN domain and Lys383 acetylation site of STAT6.</p><p><strong>Conclusions: </strong>TRIM24 suppresses Th2-mediated AR by regulating the acetylation of STAT6.</p>","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"15 5","pages":"603-613"},"PeriodicalIF":4.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2b/b7/aair-15-603.PMC10570786.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41188260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-29DOI: 10.29328/journal.aaai.1001032
Yong-Qing Zhu, Xiao-Yan Meng, Jing-Hua Yang
Background: Asthma, a chronic inflammatory respiratory ailment, is characterized by variable airflow obstruction and heightened bronchial reactivity. Despite therapeutic advancements, a comprehensive comprehension of its underlying metabolic mechanisms remains elusive. Metabolomics has emerged as a powerful approach to investigating the complex connections between serum metabolites and disease pathogenesis. However, exploring the causal relationship between serum metabolites and asthma susceptibility demands meticulous examination to unveil potential therapeutic targets. Methods: Mendelian randomization (MR) approach was explored to investigate the potential causal associations between serum metabolites and asthma risk. The main analysis employed the inverse variance weighted method, supported by supplementary approaches such as MR-Egger, weighted median, weighted mode, and sample mode. To enhance the strength and credibility of our results, we conducted sensitivity analyses encompassing heterogeneity testing, assessment of horizontal pleiotropy, and leave-one-out analysis. Additionally, pathway enrichment analysis was performed to further elucidate the results. Results: We identified 18 known and 12 unknown metabolites with potential associations with asthma risk. Among known metabolites, seven exhibited protective effects (e.g., 4-acetamidobutanoate, allantoin, kynurenine, oxidized bilirubin*), while eleven were considered risk factors (e.g., ornithine, N-acetylornithine, alanine). Through the integration of four additional MR models and sensitivity analyses, we revealed a connection between 4-acetamidobutanoate and approximately 6% lower asthma risk (OR = 0.94, 95% CI: 0.90–0.98). Conclusions: Our MR analysis uncovered protective and risk-associated metabolites, alongside 12 unknown metabolites linked to asthma. Notably, 4-acetamidobutanoate demonstrated a nominal 6% reduction in asthma risk, highlighting its potential significance.
{"title":"Causal Link between Human Blood Metabolites and Asthma: An Investigation Using Mendelian Randomization","authors":"Yong-Qing Zhu, Xiao-Yan Meng, Jing-Hua Yang","doi":"10.29328/journal.aaai.1001032","DOIUrl":"https://doi.org/10.29328/journal.aaai.1001032","url":null,"abstract":"Background: Asthma, a chronic inflammatory respiratory ailment, is characterized by variable airflow obstruction and heightened bronchial reactivity. Despite therapeutic advancements, a comprehensive comprehension of its underlying metabolic mechanisms remains elusive. Metabolomics has emerged as a powerful approach to investigating the complex connections between serum metabolites and disease pathogenesis. However, exploring the causal relationship between serum metabolites and asthma susceptibility demands meticulous examination to unveil potential therapeutic targets. Methods: Mendelian randomization (MR) approach was explored to investigate the potential causal associations between serum metabolites and asthma risk. The main analysis employed the inverse variance weighted method, supported by supplementary approaches such as MR-Egger, weighted median, weighted mode, and sample mode. To enhance the strength and credibility of our results, we conducted sensitivity analyses encompassing heterogeneity testing, assessment of horizontal pleiotropy, and leave-one-out analysis. Additionally, pathway enrichment analysis was performed to further elucidate the results. Results: We identified 18 known and 12 unknown metabolites with potential associations with asthma risk. Among known metabolites, seven exhibited protective effects (e.g., 4-acetamidobutanoate, allantoin, kynurenine, oxidized bilirubin*), while eleven were considered risk factors (e.g., ornithine, N-acetylornithine, alanine). Through the integration of four additional MR models and sensitivity analyses, we revealed a connection between 4-acetamidobutanoate and approximately 6% lower asthma risk (OR = 0.94, 95% CI: 0.90–0.98). Conclusions: Our MR analysis uncovered protective and risk-associated metabolites, alongside 12 unknown metabolites linked to asthma. Notably, 4-acetamidobutanoate demonstrated a nominal 6% reduction in asthma risk, highlighting its potential significance.","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"110 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2023-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81578558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: The abnormal expression of tight junction (TJ) plays a vital role in the pathogenesis of chronic rhinosinusitis with nasal polyps (CRSwNP). However, there is no appropriate tool to distinguish and diagnose epithelial barrier defects in clinical practice. This study aimed to evaluate the predictive value of claudin-3 for epithelial barrier dysfunction in CRSwNP.
Methods: In this study, TJ protein levels were evaluated by real-time quantitative polymerase chain reaction, immunofluorescent, and immunohistochemistry staining in control subjects and CRSwNP patients. The receiver operating characteristic (ROC) curve was created to assess the predictive value of TJ breakdown in clinical outcomes. In vitro, human nasal epithelial cells were cultured at the air-liquid interface to analyze the transepithelial electrical resistance (TER) level.
Results: The expression levels of occludin, tricellulin, claudin-3, and claudin-10 were decreased (all P < 0.05), and those of claudin-1 was increased (P < 0.05) in CRSwNP patients as compared to healthy subjects. Additionally, claudin-3 and occludin levels were negatively correlated with the computed tomography score in CRSwNP (all P < 0.05), and the ROC curve indicated that the claudin-3 level had the most predictive accuracy in evaluating epithelial barrier disruption (area under the curve = 0.791, P < 0.001). Finally, the time-series analysis showed the highest correlation coefficient between TER and claudin-3 (cross-correlation function = 0.75).
Conclusion: In this study, we suggest that claudin-3 could be a valuable biomarker for predicting nasal epithelial barrier defects and disease severity in CRSwNP.
{"title":"Predictive Significance of Claudin-3 for Epithelial Barrier Dysfunction in Chronic Rhinosinusitis With Nasal Polyps.","authors":"Zhi-Qun Huang, Jing Ye, Jing Liu, Li-Ying Sun, Hsiao Hui Ong, Yong-Hao Wei, Shu-Cai Fu, Xiao-Xun Hu, Yu Xu, De-Yun Wang","doi":"10.4168/aair.2023.15.4.512","DOIUrl":"https://doi.org/10.4168/aair.2023.15.4.512","url":null,"abstract":"<p><strong>Purpose: </strong>The abnormal expression of tight junction (TJ) plays a vital role in the pathogenesis of chronic rhinosinusitis with nasal polyps (CRSwNP). However, there is no appropriate tool to distinguish and diagnose epithelial barrier defects in clinical practice. This study aimed to evaluate the predictive value of claudin-3 for epithelial barrier dysfunction in CRSwNP.</p><p><strong>Methods: </strong>In this study, TJ protein levels were evaluated by real-time quantitative polymerase chain reaction, immunofluorescent, and immunohistochemistry staining in control subjects and CRSwNP patients. The receiver operating characteristic (ROC) curve was created to assess the predictive value of TJ breakdown in clinical outcomes. <i>In vitro,</i> human nasal epithelial cells were cultured at the air-liquid interface to analyze the transepithelial electrical resistance (TER) level.</p><p><strong>Results: </strong>The expression levels of occludin, tricellulin, claudin-3, and claudin-10 were decreased (all <i>P</i> < 0.05), and those of claudin-1 was increased (<i>P</i> < 0.05) in CRSwNP patients as compared to healthy subjects. Additionally, claudin-3 and occludin levels were negatively correlated with the computed tomography score in CRSwNP (all <i>P</i> < 0.05), and the ROC curve indicated that the claudin-3 level had the most predictive accuracy in evaluating epithelial barrier disruption (area under the curve = 0.791, <i>P</i> < 0.001). Finally, the time-series analysis showed the highest correlation coefficient between TER and claudin-3 (cross-correlation function = 0.75).</p><p><strong>Conclusion: </strong>In this study, we suggest that claudin-3 could be a valuable biomarker for predicting nasal epithelial barrier defects and disease severity in CRSwNP.</p>","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"15 4","pages":"512-525"},"PeriodicalIF":4.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/da/70/aair-15-512.PMC10359644.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9852534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-01DOI: 10.4168/aair.2023.15.4.496
Mi-Ae Kim, Jeong-Hee Choi, Yoo-Seob Shin, Hae-Sim Park, Young-Min Ye
Purpose: The prevalence of chronic urticaria (CU) is increasing worldwide, and it imposes a major burden on patients. Few studies have evaluated the efficacy of second-line treatments of CU, particularly for patients being considered for costly third-line treatments such as omalizumab. We compared the efficacy and safety of second-line treatments of CU refractory to standard doses of nonsedating H1-antihistamines (nsAHs).
Methods: This 4-week, prospective, randomized, open-label trial divided patients into 4 treatment groups: 4-fold updosing of nsAHs, multiple combination of 4 nsAHs, switching to other nsAHs, and adjunctive H2-receptor antagonist. The clinical outcomes included urticaria control status, symptoms, and rescue medication use.
Results: This study included 109 patients. After 4 weeks of second-line treatment, urticaria was well-controlled, partly controlled, and uncontrolled in 43.1%, 36.7%, and 20.2% of patients, respectively. Complete control of CU was achieved in 20.4% of patients. Among the patients with high-dose nsAHs, the proportion with well-controlled status was higher compared to the patients who received standard doses (51.9% vs. 34.5%, P = 0.031). No significant difference was observed in the proportion of well-controlled cases between the updosing and combination treatment groups (57.7% vs. 46.4%, P = 0.616). However, increasing the dose of nsAHs 4-fold was associated with a higher rate of complete symptom control compared to multiple combination treatment with 4 nsAHs (40.0% vs. 10.7%, P = 0.030). Logistic regression analysis confirmed the higher efficacy of updosing of nsAHs for complete control of CU compared to the other treatment strategies (odds ratio, 0.180; P = 0.020).
Conclusions: In patients with CU refractory to standard doses of nsAHs, both updosing of nsAHs 4-fold and multiple combination treatment with 4 nsAHs increased the rate of well-controlled cases without causing significant adverse effects. Updosing of nsAHs is more effective for complete CU control than combination treatment.
目的:慢性荨麻疹(CU)的患病率在全球范围内呈上升趋势,给患者带来了沉重的负担。很少有研究评估CU二线治疗的疗效,特别是考虑接受昂贵的三线治疗(如omalizumab)的患者。我们比较了难治CU的二线治疗与标准剂量非镇静h1 -抗组胺药(nsAHs)的疗效和安全性。方法:这项为期4周的前瞻性、随机、开放标签试验将患者分为4个治疗组:4倍增加nsAHs, 4种nsAHs的多重联合,切换到其他nsAHs,以及辅助h2受体拮抗剂。临床结果包括荨麻疹控制状况、症状和抢救用药情况。结果:本研究纳入109例患者。经过4周的二线治疗,分别有43.1%、36.7%和20.2%的患者荨麻疹得到良好控制、部分控制和未控制。20.4%的患者CU得到完全控制。在高剂量nsAHs患者中,控制良好的比例高于接受标准剂量的患者(51.9% vs. 34.5%, P = 0.031)。两组对照良好的病例比例差异无统计学意义(57.7% vs 46.4%, P = 0.616)。然而,与4种nsAHs的多重联合治疗相比,将nsAHs剂量增加4倍与更高的完全症状控制率相关(40.0%比10.7%,P = 0.030)。Logistic回归分析证实,与其他治疗策略相比,增加nsAHs剂量完全控制CU的疗效更高(优势比,0.180;P = 0.020)。结论:在标准剂量非甾体类药物难治性CU患者中,非甾体类药物4倍加药和4种非甾体类药物多次联合治疗均可增加控制良好病例的发生率,且无明显不良反应。与联合治疗相比,增加nsAHs对完全控制CU更有效。
{"title":"Efficacy of Second-Line Treatments in Chronic Urticaria Refractory to Standard Dose Antihistamines.","authors":"Mi-Ae Kim, Jeong-Hee Choi, Yoo-Seob Shin, Hae-Sim Park, Young-Min Ye","doi":"10.4168/aair.2023.15.4.496","DOIUrl":"https://doi.org/10.4168/aair.2023.15.4.496","url":null,"abstract":"<p><strong>Purpose: </strong>The prevalence of chronic urticaria (CU) is increasing worldwide, and it imposes a major burden on patients. Few studies have evaluated the efficacy of second-line treatments of CU, particularly for patients being considered for costly third-line treatments such as omalizumab. We compared the efficacy and safety of second-line treatments of CU refractory to standard doses of nonsedating H<sub>1</sub>-antihistamines (nsAHs).</p><p><strong>Methods: </strong>This 4-week, prospective, randomized, open-label trial divided patients into 4 treatment groups: 4-fold updosing of nsAHs, multiple combination of 4 nsAHs, switching to other nsAHs, and adjunctive H<sub>2</sub>-receptor antagonist. The clinical outcomes included urticaria control status, symptoms, and rescue medication use.</p><p><strong>Results: </strong>This study included 109 patients. After 4 weeks of second-line treatment, urticaria was well-controlled, partly controlled, and uncontrolled in 43.1%, 36.7%, and 20.2% of patients, respectively. Complete control of CU was achieved in 20.4% of patients. Among the patients with high-dose nsAHs, the proportion with well-controlled status was higher compared to the patients who received standard doses (51.9% vs. 34.5%, <i>P</i> = 0.031). No significant difference was observed in the proportion of well-controlled cases between the updosing and combination treatment groups (57.7% vs. 46.4%, <i>P</i> = 0.616). However, increasing the dose of nsAHs 4-fold was associated with a higher rate of complete symptom control compared to multiple combination treatment with 4 nsAHs (40.0% vs. 10.7%, <i>P</i> = 0.030). Logistic regression analysis confirmed the higher efficacy of updosing of nsAHs for complete control of CU compared to the other treatment strategies (odds ratio, 0.180; <i>P</i> = 0.020).</p><p><strong>Conclusions: </strong>In patients with CU refractory to standard doses of nsAHs, both updosing of nsAHs 4-fold and multiple combination treatment with 4 nsAHs increased the rate of well-controlled cases without causing significant adverse effects. Updosing of nsAHs is more effective for complete CU control than combination treatment.</p>","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"15 4","pages":"496-511"},"PeriodicalIF":4.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a6/92/aair-15-496.PMC10359646.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9854680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-01Epub Date: 2023-02-28DOI: 10.4168/aair.2023.15.4.451
Thi Bich Tra Cao, Quang Luu Quoc, Eun-Mi Yang, Ji-Young Moon, Yoo Seob Shin, Min Sook Ryu, Youngwoo Choi, Hae-Sim Park
Purpose: Severe asthma (SA) is characterized by persistent airway inflammation and remodeling, followed by lung function decline. The present study aimed to evaluate the role of tissue inhibitor of metalloproteinase-1 (TIMP-1) in the pathogenesis of SA.
Methods: We enrolled 250 adult asthmatics (54 with SA and 196 with non-SA) and 140 healthy controls (HCs). Serum TIMP-1 levels were determined by enzyme-linked immunosorbent assay. The release of TIMP-1 from airway epithelial cells (AECs) in response to stimuli as well as the effects of TIMP-1 on the activations of eosinophils and macrophages were evaluated in vitro and in vivo.
Results: Significantly higher levels of serum TIMP-1 were noted in asthmatics than in HCs, in the SA group than in non-SA group, and in the type 2 SA group than in non-type 2 SA group (P < 0.01 for all). A negative correlation between serum TIMP-1 and FEV1% values (r = -0.400, P = 0.003) was noted in the SA group. In vitro study demonstrated that TIMP-1 was released from AECs in response to poly I:C, IL-13, eosinophil extracellular traps (EETs) and in coculture with eosinophils. TIMP-1-stimulated mice showed eosinophilic airway inflammation, which was not completely suppressed by steroid treatment. In vitro and in vivo functional studies showed that TIMP-1 directly activated eosinophils and macrophages, and induced the release of EETs and macrophages to polarize toward M2 subset, which was suppressed by anti-TIMP-1 antibody.
Conclusions: These findings suggest that TIMP-1 enhances eosinophilic airway inflammation and that serum TIMP-1 may be a potential biomarker and/or therapeutic target for type 2 SA.
目的:重症哮喘(SA)的特征是持续的气道炎症和重塑,随后肺功能下降。本研究旨在评估组织金属蛋白酶抑制剂-1(TIMP-1)在哮喘发病机制中的作用:我们招募了 250 名成年哮喘患者(54 名 SA 患者和 196 名非 SA 患者)和 140 名健康对照组(HCs)。血清 TIMP-1 水平通过酶联免疫吸附试验测定。在体外和体内评估了气道上皮细胞(AECs)在刺激下释放 TIMP-1 的情况以及 TIMP-1 对嗜酸性粒细胞和巨噬细胞活化的影响:哮喘患者的血清 TIMP-1 水平明显高于 HCs,SA 组高于非 SA 组,2 型 SA 组高于非 2 型 SA 组(P 均<0.01)。在 SA 组中,血清 TIMP-1 与 FEV1% 值呈负相关(r = -0.400,P = 0.003)。体外研究表明,在聚 I:C、IL-13、嗜酸性粒细胞胞外捕获物(EETs)以及与嗜酸性粒细胞共培养的情况下,AECs 会释放 TIMP-1。受 TIMP-1 刺激的小鼠表现出嗜酸性粒细胞气道炎症,类固醇治疗并不能完全抑制这种炎症。体外和体内功能研究表明,TIMP-1 可直接激活嗜酸性粒细胞和巨噬细胞,并诱导 EETs 的释放和巨噬细胞向 M2 亚群极化,抗 TIMP-1 抗体可抑制这种极化:这些研究结果表明,TIMP-1 可增强嗜酸性粒细胞气道炎症,血清 TIMP-1 可能是 2 型 SA 的潜在生物标记物和/或治疗靶点。
{"title":"Tissue Inhibitor of Metalloproteinase-1 Enhances Eosinophilic Airway Inflammation in Severe Asthma.","authors":"Thi Bich Tra Cao, Quang Luu Quoc, Eun-Mi Yang, Ji-Young Moon, Yoo Seob Shin, Min Sook Ryu, Youngwoo Choi, Hae-Sim Park","doi":"10.4168/aair.2023.15.4.451","DOIUrl":"10.4168/aair.2023.15.4.451","url":null,"abstract":"<p><strong>Purpose: </strong>Severe asthma (SA) is characterized by persistent airway inflammation and remodeling, followed by lung function decline. The present study aimed to evaluate the role of tissue inhibitor of metalloproteinase-1 (TIMP-1) in the pathogenesis of SA.</p><p><strong>Methods: </strong>We enrolled 250 adult asthmatics (54 with SA and 196 with non-SA) and 140 healthy controls (HCs). Serum TIMP-1 levels were determined by enzyme-linked immunosorbent assay. The release of TIMP-1 from airway epithelial cells (AECs) in response to stimuli as well as the effects of TIMP-1 on the activations of eosinophils and macrophages were evaluated <i>in vitro</i> and <i>in vivo</i>.</p><p><strong>Results: </strong>Significantly higher levels of serum TIMP-1 were noted in asthmatics than in HCs, in the SA group than in non-SA group, and in the type 2 SA group than in non-type 2 SA group (<i>P</i> < 0.01 for all). A negative correlation between serum TIMP-1 and FEV<sub>1</sub>% values (<i>r</i> = -0.400, <i>P</i> = 0.003) was noted in the SA group. <i>In vitro</i> study demonstrated that TIMP-1 was released from AECs in response to poly I:C, IL-13, eosinophil extracellular traps (EETs) and in coculture with eosinophils. TIMP-1-stimulated mice showed eosinophilic airway inflammation, which was not completely suppressed by steroid treatment. <i>In vitro</i> and <i>in vivo</i> functional studies showed that TIMP-1 directly activated eosinophils and macrophages, and induced the release of EETs and macrophages to polarize toward M2 subset, which was suppressed by anti-TIMP-1 antibody.</p><p><strong>Conclusions: </strong>These findings suggest that TIMP-1 enhances eosinophilic airway inflammation and that serum TIMP-1 may be a potential biomarker and/or therapeutic target for type 2 SA.</p>","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"15 4","pages":"451-472"},"PeriodicalIF":4.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d0/93/aair-15-451.PMC10359643.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9857133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-01DOI: 10.4168/aair.2023.15.4.437
Jin-Young Min, Jin Youp Kim, Chung Man Sung, Seon Tae Kim, Hyun-Jin Cho, Sue Jean Mun, Sung-Woo Cho, Sang Duk Hong, Gwanghui Ryu, Kyoung Rai Cho, Young Hyo Kim, Soo Kyoung Park, Dong-Kyu Kim, Dong Hoon Lee, Sung Jae Heo, Ki-Il Lee, Su Jin Kim, Sangjun Lee, Ji-Hun Mo, Seung-Heon Shin, Dae Woo Kim
Purpose: Cluster analyses on inflammatory markers of chronic rhinosinusitis (CRS) in Asians from multicenter data are lacking. This multicenter study aimed to identify the endotypes of CRS in Koreans and to evaluate the relationship between the endotypes and clinical parameters.
Methods: Nasal tissues were obtained from patients with CRS and controls who underwent surgery. The endotypes of CRS were investigated by measuring interleukin (IL)-5, interferon (IFN)-γ, IL-17A, IL-22, IL-1β, IL-6, IL-8, matrix metalloproteinase-9, eotaxin-3, eosinophil cationic protein, myeloperoxidase (MPO), human neutrophil elastase (HNE), periostin, transforming growth factor-β1, total immunoglobulin E (IgE), and staphylococcal enterotoxin (SE)-specific IgE. We performed hierarchical cluster analysis and evaluated the phenotype, comorbidities, and Lund-Mackay computed tomography (LM CT) score in each cluster.
Results: Five clusters and 3 endotypes were extracted from 244 CRS patients: cluster 1 had no upregulated mediators compared to the other clusters (mild mixed inflammatory CRS); clusters 2, 3, and 4 had higher concentrations of neutrophil-associated mediators including HNE, IL-8, IL-17A, and MPO (T3 CRS); and cluster 5 had higher levels of eosinophil-associated mediators (T2 CRS). SE-specific IgE was undetectable in T3 CRS and had low detectable levels (6.2%) even in T2 CRS. The CRS with nasal polyps (CRSwNP) phenotype and LM CT scores showed no significant differences between T2 and T3 CRS, while the incidence of comorbid asthma was higher in T2 CRS than T3 CRS. In T3 clusters, higher levels of neutrophilic markers were associated with disease severity and CRSwNP phenotype.
Conclusions: In Koreans, there is a distinct T3 CRS endotype showing a high proportion of CRSwNP and severe disease extent, along with T2 CRS.
{"title":"Inflammatory Endotypes of Chronic Rhinosinusitis in the Korean Population: Distinct Expression of Type 3 Inflammation.","authors":"Jin-Young Min, Jin Youp Kim, Chung Man Sung, Seon Tae Kim, Hyun-Jin Cho, Sue Jean Mun, Sung-Woo Cho, Sang Duk Hong, Gwanghui Ryu, Kyoung Rai Cho, Young Hyo Kim, Soo Kyoung Park, Dong-Kyu Kim, Dong Hoon Lee, Sung Jae Heo, Ki-Il Lee, Su Jin Kim, Sangjun Lee, Ji-Hun Mo, Seung-Heon Shin, Dae Woo Kim","doi":"10.4168/aair.2023.15.4.437","DOIUrl":"https://doi.org/10.4168/aair.2023.15.4.437","url":null,"abstract":"<p><strong>Purpose: </strong>Cluster analyses on inflammatory markers of chronic rhinosinusitis (CRS) in Asians from multicenter data are lacking. This multicenter study aimed to identify the endotypes of CRS in Koreans and to evaluate the relationship between the endotypes and clinical parameters.</p><p><strong>Methods: </strong>Nasal tissues were obtained from patients with CRS and controls who underwent surgery. The endotypes of CRS were investigated by measuring interleukin (IL)-5, interferon (IFN)-γ, IL-17A, IL-22, IL-1β, IL-6, IL-8, matrix metalloproteinase-9, eotaxin-3, eosinophil cationic protein, myeloperoxidase (MPO), human neutrophil elastase (HNE), periostin, transforming growth factor-β1, total immunoglobulin E (IgE), and staphylococcal enterotoxin (SE)-specific IgE. We performed hierarchical cluster analysis and evaluated the phenotype, comorbidities, and Lund-Mackay computed tomography (LM CT) score in each cluster.</p><p><strong>Results: </strong>Five clusters and 3 endotypes were extracted from 244 CRS patients: cluster 1 had no upregulated mediators compared to the other clusters (mild mixed inflammatory CRS); clusters 2, 3, and 4 had higher concentrations of neutrophil-associated mediators including HNE, IL-8, IL-17A, and MPO (T3 CRS); and cluster 5 had higher levels of eosinophil-associated mediators (T2 CRS). SE-specific IgE was undetectable in T3 CRS and had low detectable levels (6.2%) even in T2 CRS. The CRS with nasal polyps (CRSwNP) phenotype and LM CT scores showed no significant differences between T2 and T3 CRS, while the incidence of comorbid asthma was higher in T2 CRS than T3 CRS. In T3 clusters, higher levels of neutrophilic markers were associated with disease severity and CRSwNP phenotype.</p><p><strong>Conclusions: </strong>In Koreans, there is a distinct T3 CRS endotype showing a high proportion of CRSwNP and severe disease extent, along with T2 CRS.</p>","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"15 4","pages":"437-450"},"PeriodicalIF":4.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/da/b4/aair-15-437.PMC10359642.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9857134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-01DOI: 10.4168/aair.2023.15.4.526
Na Young Kim, Eun Shin, Sun-Ju Byeon, Seok Jin Hong, Sung Hun Kang, Taehoon Lee, Tae-Bum Kim, Jeong-Hee Choi
Zonulin is a regulator of epithelial and endothelial barrier function. It regulates intestinal permeability through disrupting tight junctions. Defective epithelial barrier function is a hallmark of airway inflammation in asthma. This study aimed to investigate the role of zonulin in the pathogenesis of severe asthma. We enrolled 56 adult patients with asthma (29 severe asthma and 27 mild-to-moderate asthma) and 33 normal controls. The clinical data, sera, and lung tissues of the patients were provided by the Cohort for Reality and Evolution of adult Asthma in Korea (COREA) and the Biobank of Soonchunhyang University Bucheon Hospital, South Korea. Serum zonulin levels were estimated using an enzyme-linked immunosorbent assay, and zonulin expression in the bronchial tissue was evaluated by immunohistochemical staining. The serum zonulin levels were significantly higher in patients with severe asthma (51.98 ± 19.66 ng/mL) than in those with mild-to-moderate asthma and normal controls (26.35 ± 13.70 vs. 17.26 ± 10.29 ng/mL, P < 0.001). They significantly correlated with percent predicted forced expiratory volume in one second (%FEV1) (r = −0.35, P = 0.009). The zonulin expression in the bronchial epithelium was greater in patients with severe asthma. A serum zonulin cutoff value to distinguish between severe and mild-to-moderate asthmatics was 38.83 ng/mL. Zonulin may play an important role in the pathogenesis of severe asthma, and serum zonulin could be a potential biomarker for severe asthma.
Zonulin是上皮和内皮屏障功能的调节剂。它通过破坏紧密连接来调节肠道通透性。上皮屏障功能缺陷是哮喘气道炎症的标志。本研究旨在探讨zonulin在重症哮喘发病机制中的作用。我们招募了56名成年哮喘患者(29名重度哮喘患者和27名轻中度哮喘患者)和33名正常对照。患者的临床资料、血清和肺组织由韩国成人哮喘现实和进化队列(COREA)和韩国顺春香大学富川医院生物银行提供。使用酶联免疫吸附法估计血清中zonulin的水平,并通过免疫组织化学染色评估支气管组织中zonulin的表达。重度哮喘患者血清zonulin水平(51.98±19.66 ng/mL)明显高于轻中度哮喘和正常对照组(26.35±13.70 vs. 17.26±10.29 ng/mL, P < 0.001)。它们与预测一秒钟用力呼气量的百分比(%FEV1)显著相关(r = -0.35, P = 0.009)。支气管上皮zonulin的表达在严重哮喘患者中较高。区分重度和轻中度哮喘患者的血清带蛋白临界值为38.83 ng/mL。Zonulin可能在严重哮喘的发病机制中发挥重要作用,血清Zonulin可能是严重哮喘的潜在生物标志物。
{"title":"Serum Zonulin Is a Biomarker for Severe Asthma.","authors":"Na Young Kim, Eun Shin, Sun-Ju Byeon, Seok Jin Hong, Sung Hun Kang, Taehoon Lee, Tae-Bum Kim, Jeong-Hee Choi","doi":"10.4168/aair.2023.15.4.526","DOIUrl":"https://doi.org/10.4168/aair.2023.15.4.526","url":null,"abstract":"Zonulin is a regulator of epithelial and endothelial barrier function. It regulates intestinal permeability through disrupting tight junctions. Defective epithelial barrier function is a hallmark of airway inflammation in asthma. This study aimed to investigate the role of zonulin in the pathogenesis of severe asthma. We enrolled 56 adult patients with asthma (29 severe asthma and 27 mild-to-moderate asthma) and 33 normal controls. The clinical data, sera, and lung tissues of the patients were provided by the Cohort for Reality and Evolution of adult Asthma in Korea (COREA) and the Biobank of Soonchunhyang University Bucheon Hospital, South Korea. Serum zonulin levels were estimated using an enzyme-linked immunosorbent assay, and zonulin expression in the bronchial tissue was evaluated by immunohistochemical staining. The serum zonulin levels were significantly higher in patients with severe asthma (51.98 ± 19.66 ng/mL) than in those with mild-to-moderate asthma and normal controls (26.35 ± 13.70 vs. 17.26 ± 10.29 ng/mL, P < 0.001). They significantly correlated with percent predicted forced expiratory volume in one second (%FEV1) (r = −0.35, P = 0.009). The zonulin expression in the bronchial epithelium was greater in patients with severe asthma. A serum zonulin cutoff value to distinguish between severe and mild-to-moderate asthmatics was 38.83 ng/mL. Zonulin may play an important role in the pathogenesis of severe asthma, and serum zonulin could be a potential biomarker for severe asthma.","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"15 4","pages":"526-535"},"PeriodicalIF":4.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6a/98/aair-15-526.PMC10359649.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9854682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-01DOI: 10.4168/aair.2023.15.4.416
Sang-Heon Kim
https://e-aair.org A wide array of inflammatory cytokines and mediators play roles in immune response and chronic inflammation in severe asthma (SA). Monoclonal antibodies targeting some of these molecules have shown clinical efficacy in reducing exacerbations and improving asthma control in SA.1 While biologic treatments, including anti-type 2 (T2) cytokines, such as interleukin (IL)-5, IL-4, and IL-13, and epithelial cell-derived alarmin thymic stromal lymphopoietin (TSLP), are now available in the clinical practice, many SA patients remain uncontrolled even with these treatments. Thus, a new therapeutic approach is needed to modulate inflammatory responses, not fully abrogated with current standard care and available biologics.
{"title":"Roles of Tissue Inhibitor of Metalloproteinase-1 in Severe Asthma.","authors":"Sang-Heon Kim","doi":"10.4168/aair.2023.15.4.416","DOIUrl":"https://doi.org/10.4168/aair.2023.15.4.416","url":null,"abstract":"https://e-aair.org A wide array of inflammatory cytokines and mediators play roles in immune response and chronic inflammation in severe asthma (SA). Monoclonal antibodies targeting some of these molecules have shown clinical efficacy in reducing exacerbations and improving asthma control in SA.1 While biologic treatments, including anti-type 2 (T2) cytokines, such as interleukin (IL)-5, IL-4, and IL-13, and epithelial cell-derived alarmin thymic stromal lymphopoietin (TSLP), are now available in the clinical practice, many SA patients remain uncontrolled even with these treatments. Thus, a new therapeutic approach is needed to modulate inflammatory responses, not fully abrogated with current standard care and available biologics.","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"15 4","pages":"416-418"},"PeriodicalIF":4.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d8/69/aair-15-416.PMC10359650.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9906439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}